Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-04-05
2010-11-23
Landsman, Robert (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07838239
ABSTRACT:
A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed.
REFERENCES:
patent: 4880548 (1989-11-01), Pall et al.
patent: 4925572 (1990-05-01), Pall
patent: 5210015 (1993-05-01), Gelfand et al.
patent: 5491063 (1996-02-01), Fisher et al.
patent: 5683698 (1997-11-01), Chavali et al.
patent: 6692916 (2004-02-01), Bevilacqua et al.
patent: 7332631 (2008-02-01), Hogarth et al.
patent: 2001/0006789 (2001-07-01), Maino et al.
patent: 2002/0006613 (2002-01-01), Shyjan et al.
patent: 2002/0048566 (2002-04-01), El-Deiry et al.
patent: 2002/0106684 (2002-08-01), Kopreski
patent: 2003/0138781 (2003-07-01), Whitehead
patent: 2003/0148345 (2003-08-01), Kopreski
patent: 2004/0265864 (2004-12-01), Mitsuhashi
patent: 2007/0196835 (2007-08-01), Bankaitis-Davis et al.
patent: 2008/0206761 (2008-08-01), Mitsuhashi
patent: 2008/0261207 (2008-10-01), Mitsuhashi
patent: 1243274 (2002-09-01), None
patent: WO 98/47004 (1998-10-01), None
patent: WO 00/76492 (2000-12-01), None
patent: WO 03/040404 (2003-05-01), None
patent: WO 03/059333 (2003-07-01), None
patent: WO03090694 (2003-11-01), None
patent: WO 03/099312 (2003-12-01), None
patent: WO 2005/044792 (2005-05-01), None
patent: WO 2005/115115 (2005-12-01), None
patent: WO 2006/110091 (2006-10-01), None
patent: WO 2006/116721 (2006-11-01), None
patent: 2008/106451 (2008-09-01), None
European Patent Office, European Search Report, Mar. 6, 2009.
Aggarwal, B. B., et al., “The Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion,” Curr. Drug Targets Inflamm. Allergy, vol. 1, No. 4, Dec. 2002, pp. 327-341.
Ames et al., “Are vitamin and mineral deficiencies a major cancer risk?” Nature, 2002, 2: 694-704.
Bush et al., Cancer Chemoresistance: The relationship Between P53 and Multidrug Transporters, Int J Cancer, 2002, vol. 98, pp. 323-330.
Cardullo, et al., Detection of Nucleic Acid Hybridization by Nonradiative Fluorescence Resonance Energy Transfer, Proc. Nat'l Acad. Sci., 1988, vol. 85, pp. 8790-8794, USA.
Chaudhary et al., Prediction of response to infliximab in Crohn's disease, Digestive and Liver Disease, 2005, vol. 37, Issue 8, pp. 559-563.
Chiaretti S et al., Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival, Blood, Apr. 1, 2004, vol. 103, Issue 7, pp. 2771-2778.
Flores Mona G et al., In vitro evaluation of the effects of candidate immunosuppressive drugs: flow cytometry and quantitative real-time PCR as two independent and correlated read-outs, Journal of Immunological Methods, Jun. 2004, vol. 289, Issue 1-2, pp. 123-135.
Fujikado et al., Identification of arthritis related gene clusters by microarray analysis of two independent mouse models for rheumatoid arthritis, Arthritis Research and Therapy, 2006, vol. 8, pp. 1-13.
Ghosh et al., Anti-TNF therapy in Crohn's disease, Novartis Foundation Symposium, 2004, vol. 263, pp. 193-218.
Giacomelli et al., Combination therapy with cyclosporine and methotrexate in pateints with early rheumatoid arthritis soon inhibits TNF production without decreasing TNF mRNA level. An in vivo and in vitro study, Clinical and Experimental Rheumatology, 2002, vol. 20, pp. 365-372.
Haertel C et al., Dose-dependent Immunomodulatory Effects of Acetylsalicylic Acid and Indomethacin in Human Whole Blood: Potential Role of Cyclooxygenase-2 Inhibition, Scandinavian Journal Immunology, Oct. 2004, vol. 60, Issue 4, pp. 412-420.
Hess et al., The Hydroxylamine of sulfamethoxazole Synergizes with FK506 and Cyclosporin A, Inhibiting T-Cell Proliferation, The Journal of Pharmacology and Experimental Techniques, Dec. 1996, vol. 281, Issue 1, pp. 540-548.
Juhasz et al., Quantification of Chemotherapeuytic Target Gene mRNA Expression in Human Breast Cancer Biopsies: Comparison of Real-Time Reverse Transcription-PCR vs. Relative Quantification Reverse Transcription-PCR Utilizing DNA Sequencer Analysis of PCR Product, Journal of Clinical Laboratory Analysis, 2003, vol. 17, pp. 184-194.
Klein N J et al., Ex-Vivo Assessment of Candidate Anti-Inflammatory Agents in the Treatment of Gram Negative Sepsis, Immunology and Infectious Diseases, 1994, vol. 4, Issue 1, pp. 33-35.
Leung, S. Y., et al., “Expression Profiling Identifies Chemokine (C-C Motif) Ligand 18 as an Independent Prognostic Indicator in Gastric Cancer,” Gastroenterology, vol. 127, No. 2, Aug. 2004, pp. 457-469.
Mascheretti et al., Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab, The Pharmacogenomics Journal, 2002, vol. 2, Issue 2, pp. 127-136.
Mehmut et al., Fas Ligand and TNF-Related Apoptosis-Inducing Ligand Induction on Infiltrating Lymphocytes in Bladder Carcinoma by Bacillus Calmette-Guerin Treatment, Urologica Internatiol, 2005, vol. 75, pp. 88-87.
Plevy et al., A Role for TNF-α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease, The Journal of Immunology, 1997, vol. 159, Issue 12, pp. 6276-6282.
Rodriguez-Caballero et al., A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation, Laboratory Investigation, 2004, vol. 84, pp. 1387-1398.
Schimanski, C. C., et al., “Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer,” Clinical Cancer Research, vol. 11, No. 5, Mar. 2005, pp. 1743-1750.
Shetty et al., Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn's Disease, American Journal of Pharmacogenomics, 2002, vol. 2, Issue 4, pp. 215-221.
Sträter, J., et al., “Expression of TRAIL and TRAIL Receptors in Colon Carcinoma: TRAIL-R1 Is an Independent Prognostic Parameter,” Clinical Cancer Research, vol. 8, No. 12, Dec. 2002, pp. 3734-3740.
Warzocha et al., Tumor Necrosis Factor Ligand-Receptor System Can Predict Treatment Outcome in Lymphoma Patients, Journal of Clinical Oncology, 1997, vol. 15, pp. 499-508.
Wouters et al., Inter- and intraindividual variation of endotoxin- and Beta(1->3)-glucan-induced cytokine responses in a whole blood assay, Toxicology and Industrial Health, 2002, vol. 18, pp. 15-27.
Younes, A., et al., “Clinical Implications of the Tumor Necrosis Factor Family in Benign and Malignant Hematologic Disorders,” Cancer, vol. 98, No. 3, Aug. 2003, pp. 458-467.
Younes, A., et al., “Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy,” J. Clin. Oncol., vol. 21, No. 18, Sep. 2003, pp. 3526-3534.
Christoph Hartel et al., Delayed Cytokine mRNA Expression Kinetics after T-Lymphocyte Costimulation: A Quantitative Measure of the Efficacy of Cyclosporin A-based Immunosuppression, Clinical Chemistry , 2002, vol. 48, Issue 12, pp. 2225-2231.
Darryl See et al., Increased Tumor Necrosis Factor Alpha (TNF-alpha) and Natural Killer Cell (NK) Function Using an Integrative Approach in Late Stage Cancers, Immunological Investigations, 2002, vol. 31, Issue 2, pp. 137-153.
European Patent Office, EP Search Report for EP 06772657.0, HITACHI.072VPC, Dec. 2, 2008.
Hiroko Matsunaga, Application of differential display to identify genes for lung cancer detection in peripheral blood, Int. J. of Cancer , 2002, vol. 100, Issue 5, pp. 593-599.
Jamila K. Adam et al., Immune responses in cancer, Pharmacology & Therapeutics, 2003, vol. 99, pp. 113-132.
Mitsuhashi Masato
Targan Stephan R.
Cedars-Sinai Medical Center
Hitachi Chemical Co. Ltd.
Hitachi Chemical Research Center Inc.
Knobbe Martens Olson & Bear LLP
Landsman Robert
LandOfFree
Methods regarding enhanced T-cell receptor-mediated tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods regarding enhanced T-cell receptor-mediated tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods regarding enhanced T-cell receptor-mediated tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248308